Cereno Scientific has announced making strong progress with its phase II clinical study with lead drug candidate CS1. The study, run in patients with pulmonary arterial hypertension, is part of Cereno's efforts to develop new and better treatments for patients suffering from common and rare cardiovascular disease. To continue pursuing this vision, the company is raising capital through a rights issue of approximately 110 million SEK.